# Leadership Group for the Infectious Diseases Clinical Research Consortium (IDCRCLG) - COVAIL DMID #22-0004

> **NIH NIH UM1** · EMORY UNIVERSITY · 2022 · $240,086

## Abstract

IDCRC LG Project Summary/Abstract:
This Infectious Diseases Clinical Research Consortium Leadership Group (IDCRCLG or LG) is a
collaborative national partnership of leading infectious diseases (ID), human immunology and clinical
research experts from eight outstanding academic institutions providing experience, guidance, global
connectivity and innovative approaches to address NIH/NIAID clinical research priorities. The emphasis
(and strength) of the LG is to facilitate, plan and help implement clinical research for respiratory and
enteric infections, malaria/tropical diseases, and sexually transmitted infections (STIs), and to respond to
emerging infectious diseases (EID). Priority research includes interventional trials and clinical research
studies for vaccines, biologics, therapeutics, diagnostics and devices targeting infectious diseases. The
LG’s experts and their programs have a historic record of accomplishment in vaccine and therapeutic clinical
research, and immunologic and pathogenesis studies for these NIAID-priority ID’s. The LG brings extensive
expertise with the conduct of Phase I-IV clinical trials including first- in-human studies, cutting-edge human
immunology, pharmacokinetics; engagement with diverse populations both nationally/internationally, sIRBs,
innovative public-private partnerships, and Investigational New Drug applications (INDs). The group also
has strong connectivity to and leverages NIH/NIAID-supported networks; extensive experience in
collaborating with industry partners and foundations, and leadership of complex administrative consortia.
This cadre of diverse infectious diseases experts has established and operates with NIAID and the
reconstituted Vaccine and Treatment Evaluation Units (VTEUs), an integrated, highly- functional, efficient
IDCRC to develop innovative scientific and operational strategies in priorities such as vaccines and STI
clinical research. The organizational structure supporting the science and operations of the LG is composed
of a Leadership Operations Center including Expert Working Groups, Key Function Committees, a Clinical
Operations Unit, a Laboratory Operations Unit, and a Statistical and Data Science Unit. Key functions of the
LG are to propose, review and prioritize innovative concepts; to enhance integration and efficiency in
operations; to form collaborative teams; to ensure quality and timely protocol implementation; to disseminate
results; to promote integration of all populations in IDCRC research across the human lifespan; and to attract,
engage and retain the next generation of scientists in ID clinical research. In addition, the LG’s experience
with EID threats, links to global partners/sites, access to the highest-level clinical and laboratory containment
facilities and to large populations has allowed it to respond rapidly (surge capacity) t o t h e C O V I D -
1 9 public health emergency. The LG’s decades of experience with public health, regulatory agencies,
product devel...

## Key facts

- **NIH application ID:** 10615472
- **Project number:** 3UM1AI148684-03S7
- **Recipient organization:** EMORY UNIVERSITY
- **Principal Investigator:** Kathleen Maletic Neuzil
- **Activity code:** UM1 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $240,086
- **Award type:** 3
- **Project period:** 2022-09-02 → 2026-11-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10615472

## Citation

> US National Institutes of Health, RePORTER application 10615472, Leadership Group for the Infectious Diseases Clinical Research Consortium (IDCRCLG) - COVAIL DMID #22-0004 (3UM1AI148684-03S7). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10615472. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*